In preclinical ex vivo and xenograft models, enasidenib has been shown to allosterically inhibit IDH2, suppress 2-HG production, and induce cellular differentiation in primary human IDH2-mutant AML cells [79]. This evidence concerns the gene IDH2 and acute myeloid leukemia.